BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
金曜日, 9 25

ACADIA Pharmaceuticals Inc

ACADNASDAQ
Trade with Public
Trade with Public
$22.18
-3.25-12.78%
近くで: Sep 23, 5:00 PM EST
$22.25
-3.18-12.5%
プレマーケット: 8:04 AM EST
PRO
なぜ動いているのか？:Acadia Pharma shares are trading lower after the company announced remlifan...
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

ACADIA Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ACADIA Pharmaceuticals (ACAD).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

2S.Buy
15Buy
3Hold
1Sell
Consensus RatingBuy# Analysts21Avg. Consensus PT$31Upside to Avg. PT+40.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 25, 2026BMO CapitalEvan David SeigermanPT CutOutperform$36→$34
Sep 25, 2026NeedhamAmi FadiaPT CutBuy$41→$35
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
Benzinga Newsdesk

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.
Benzinga Newsdesk

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved